<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:44.875Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="The Menarini Group announced marketing authorization Application for delafloxacin "
        jcr:uuid="15b45500-e6f8-49cc-8ef1-db1501e6b7f8"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-961">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2018-03-09T17:32:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398406570"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-logo-menarini-cs-icona.png"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398406573"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p style=&quot;background: white; text-align: center;&quot;>&lt;span style=&quot;color: black;&quot;>&lt;img alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/logo_M_cs.jpg&quot; style=&quot;text-align: center;&quot; />&lt;br />&#xa;&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;background: white;&quot;>&lt;span style=&quot;color: black;&quot;>The Menarini Group announced today that on March 6th 2017 it has submitted a Marketing Authorization Application for delafloxacin at the&amp;nbsp;European Medicines Agency (EMA) under the trade name Quofenix. The proposed indication for delafloxacin in&amp;nbsp;Europe&amp;nbsp;is the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), and the conclusion of the European regulatory process is expected in IIQ 2019.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;background: white; margin: 12pt 0cm;&quot;>&lt;span style=&quot;color: black;&quot;>Delafloxacin (marketed as Baxdela&lt;/span>&lt;span style=&quot;color: black;&quot;>&amp;trade;&lt;/span>&lt;span style=&quot;color: black;&quot;> in the US) is a novel anionic fluoroquinolone licensed in February 2017 to the &lt;strong>Menarini Group from Melinta Therapeutics&lt;/strong>, Inc., a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections. As part of the development and commercialization agreement, Melinta granted the Menarini Group exclusive rights to commercialize Delafloxacin in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;background: white; text-align: justify;&quot;>&lt;span style=&quot;color: black;&quot;>&amp;ldquo;The regulatory submission of delafloxacin in&amp;nbsp;Europe, after one year from the signature of the agreement,&amp;nbsp;represents an important strategic milestone for Menarini.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;background: white; text-align: justify;&quot;>&lt;span style=&quot;color: black;&quot;>ABSSSIs are among the most common human bacterial infections, and are associated with considerable morbidity, especially in subjects with underlying diseases. &lt;/span>&lt;span style=&quot;color: black;&quot;>Delafloxacin, with its broad in vitro spectrum of activity against Gram-positive, including methicillin-resistant Staphylococcus aureus (MRSA), Gram-negative and as well as atypical and anaerobe organisms, stands out as a new therapeutic option in this setting. Thanks to this new molecule, we will keep contributing to the health of patients all over the world with the high quality standards that distinguishes Menarini &amp;rdquo;,&amp;nbsp;says&amp;nbsp;&lt;strong>P.Mei General Manager of The Menarini&amp;nbsp;Group&lt;/strong>&lt;/span>&lt;span style=&quot;color: black;&quot;>.&amp;nbsp;&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;background: white; margin: 12pt 0cm;&quot;>&lt;span style=&quot;color: black;&quot;>Delafloxacin offers physicians the flexibility of fixed dose intravenous and/or oral dosage formulations, does not require therapeutic drug monitoring, can be taken with food, has a minimal potential for drug interactions, and does not require therapeutic drug monitoring. These factors, in concert with its favorable safety profile, would support the addition of delafloxacin to the ABSSSI armamentarium as an important treatment option.&lt;/span>&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-logo-menarini-cs-icona.png"/>
    </jcr:content>
</jcr:root>
